Association between cannabis potency and mental health in adolescence

被引:1
作者
Hines, Lindsey A. [1 ,2 ]
Cannings-John, Rebecca [3 ]
Hawkins, Jemma [4 ]
Bonell, Chris [5 ]
Hickman, Matthew [6 ]
Zammit, Stanley [6 ]
Adara, Linda [3 ]
Townson, Julia [3 ]
White, James [3 ,4 ]
机构
[1] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, England
[2] Univ Bath, Dept Psychol, Bath, England
[3] Cardiff Univ, Ctr Trials Res, Sch Med, Cardiff, Wales
[4] Cardiff Univ, Sch Social Sci, DECIPHer, Cardiff, Wales
[5] London Sch Hyg & Trop Med, Dept Publ Hlth Environm & Soc, London, England
[6] Cardiff Univ, MRC Ctr Neuropsychiat Genet & Genom, Cardiff, Wales
基金
英国惠康基金; 英国医学研究理事会; 英国经济与社会研究理事会;
关键词
Cannabis; THC; Depression; Anxiety; Hallucination; Adolescent;
D O I
10.1016/j.drugalcdep.2024.111359
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Introduction: In legal and illegal markets, high-potency cannabis (>10 % delta-9-tetrahydrocannabinol (THC)) is increasingly available. In adult samples higher-potency cannabis has been associated with mental health disorder but no studies have considered associations in adolescence. Methods: A population-wide study compared no, low and high potency cannabis using adolescents (aged 13-14 years) self-reported symptoms of probable depression, anxiety, and auditory hallucinations. Results: Of the 6672 participants, high-potency cannabis was used by 2.6 % (n=171) and low-potency by 0.6 % (n=38). After adjustment for sociodemographic factors, tobacco and alcohol use, in comparison to participants who had never used cannabis, people who had used high-potency but not low-potency cannabis were more likely to report symptoms of depression (odds ratio 1.59 [95 % confidence interval 1.06, 2.39), anxiety (OR 1.45, 95 % CI 0.96, 2.20), and auditory hallucinations (OR 1.56, 95 % CI 0.98, 2.47). Conclusions: High-potency cannabis use is associated with an increased risk of probable mental health disorders. Services and programming to minimise drug harms may need to be adapted to pay more attention to cannabis potency.
引用
收藏
页数:4
相关论文
共 21 条
  • [1] Angold A, 1995, INT J METHOD PSYCH, V5, P237
  • [2] User characteristics and effect profile of Butane Hash Oil: An extremely high-potency cannabis concentrate
    Chan, Gary C. K.
    Hall, Wayne
    Freeman, Tom P.
    Ferris, Jason
    Kelly, Adrian B.
    Winstock, Adam
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2017, 178 : 32 - 38
  • [3] New trends in cannabis potency in USA and Europe during the last decade (2008-2017)
    Chandra, Suman
    Radwan, Mohamed M.
    Majumdar, Chandrani G.
    Church, James C.
    Freeman, Tom P.
    ElSohly, Mahmoud A.
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2019, 269 (01) : 5 - 15
  • [4] The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis
    D'Souza, DC
    Perry, E
    MacDougall, L
    Ammerman, Y
    Cooper, T
    Wu, YT
    Braley, G
    Gueorguieva, R
    Krystal, JH
    [J]. NEUROPSYCHOPHARMACOLOGY, 2004, 29 (08) : 1558 - 1572
  • [5] The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study
    Di Forti, Marta
    Quattrone, Diego
    Freeman, Tom P.
    Tripoli, Giada
    Gayer-Anderson, Charlotte
    Quigley, Harriet
    Rodriguez, Victoria
    Jongsma, Hannah E.
    Ferraro, Laura
    La Cascia, Caterina
    La Barbera, Daniele
    Tarricone, Ilaria
    Berardi, Domenico
    Szoke, Andrei
    Arango, Celso
    Tortelli, Andrea
    Velthorst, Eva
    Bernardo, Miguel
    Del-Ben, Cristina Marta
    Menezes, Paulo Rossi
    Selten, Jean-Paul
    Jones, Peter B.
    Kirkbride, James B.
    Rutten, Bart P. F.
    de Haan, Lieuwe
    Sham, Pak C.
    van Os, Jim
    Lewis, Cathryn M.
    Lynskey, Michael
    Morgan, Craig
    Murray, Robin M.
    [J]. LANCET PSYCHIATRY, 2019, 6 (05): : 427 - 436
  • [6] Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study
    Di Forti, Marta
    Marconi, Arianna
    Carra, Elena
    Fraietta, Sara
    Trotta, Antonella
    Bonomo, Matteo
    Bianconi, Francesca
    Gardner-Sood, Poonam
    O'Connor, Jennifer
    Russo, Manuela
    Stilo, Simona A.
    Marques, Tiago Reis
    Mondelli, Valeria
    Dazzan, Paola
    Pariante, Carmine
    David, Anthony S.
    Gaughran, Fiona
    Atakan, Zerrin
    Iyegbe, Conrad
    Powell, John
    Morgan, Craig
    Lynskey, Michael
    Murray, Robin M.
    [J]. LANCET PSYCHIATRY, 2015, 2 (03): : 233 - 238
  • [7] Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?
    Freeman, Tom P.
    Morgan, Celia J. A.
    Hindocha, Chandni
    Schafer, Grainne
    Das, Ravi K.
    Curran, H. Valerie
    [J]. ADDICTION, 2014, 109 (10) : 1686 - 1694
  • [8] Hines L.A., 2020, JAMA Psychiatry
  • [9] The Effect of Age of Initiation of Cannabis Use on Psychosis, Depression, and Anxiety among Youth under 25 Years
    Hosseini, Shera
    Oremus, Mark
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2019, 64 (05): : 304 - 312
  • [10] The World Mental Health (WMH) Survey Initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI)
    Kessler, RC
    Üstün, TB
    [J]. INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH, 2004, 13 (02) : 93 - 121